热门话题-CytomX股价上涨,因与Regeneron达成扩大合作协议,里程碑付款最高可达40亿美元

路透中文
Jun 03
热门话题-<a href="https://laohu8.com/S/CTMX">CytomX</a>股价上涨,因与Regeneron达成扩大合作协议,里程碑付款最高可达40亿美元

6月3日 - ** CytomX TherapeuticsCTMX.O)股价在盘前交易中上涨3.5%,报3.27美元

** 该公司表示已与Regeneron Pharmaceuticals(REGN.O)扩大了许可协议((link)),旨在合作开发新一代双特异性抗癌疗法,该合作项目价值最高可达约40亿美元

** 此次合作将CytomX的Probody平台与Regeneron的Veloci-Bi技术相结合,旨在开发条件性激活的双特异性抗体,该抗体在靶向肿瘤的同时,能最大限度地减少对健康组织的损伤

** 作为合作扩展的一部分,在Regeneron选定另外两个药物靶点后,CytomX将获得3700万美元的付款

** Regeneron还获得了在合作框架下选择多达六个额外靶点的期权

** Regeneron将主导并资助临床前及临床开发以及商业化工作,而CytomX有权获得与开发、监管审批及销售相关的里程碑付款,以及未来产品的分级特许权使用费

** 截至收盘,CTMX年内累计下跌25.8%,REGN下跌21.9%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10